Stereotactic Ablative Body Radiotherapy for Lung Metastases: Where is the Evidence and What are We Doing With It?

Shankar Siva; Ben J Slotman

doi:10.1016/j.semradonc.2017.03.003

Stereotactic Ablative Body Radiotherapy for Lung Metastases: Where is the Evidence and What are We Doing With It?

Shankar Siva
, Ben J Slotman

Department of Radiation Oncology, Peter MacCallum Cancer Centre, East Melbourne, Australia.

Research output: Contribution to journal › Review article › Academic › peer-review

Abstract

This review provides an overview of the use of stereotactic ablative body radiotherapy (SABR) for pulmonary metastases. The local control rates after SABR are generally >90%. Whether this also translates into a significant improvement in overall survival is the subject of ongoing studies. New exciting opportunities including the integration of SABR with targeted and immune therapies as well as some competing treatment strategies are discussed.

Original language	English
Pages (from-to)	229-239
Number of pages	11
Journal	Seminars in radiation oncology
Volume	27
Issue number	3
DOIs	https://doi.org/10.1016/j.semradonc.2017.03.003
Publication status	Published - Jul 2017

Keywords

Journal Article
Review

Access to Document

10.1016/j.semradonc.2017.03.003

Cite this

@article{3cc43fc5ace3459fb1b182d54f93a709,

title = "Stereotactic Ablative Body Radiotherapy for Lung Metastases: Where is the Evidence and What are We Doing With It?",

abstract = "This review provides an overview of the use of stereotactic ablative body radiotherapy (SABR) for pulmonary metastases. The local control rates after SABR are generally >90\%. Whether this also translates into a significant improvement in overall survival is the subject of ongoing studies. New exciting opportunities including the integration of SABR with targeted and immune therapies as well as some competing treatment strategies are discussed.",

keywords = "Journal Article, Review",

author = "Shankar Siva and Slotman, \{Ben J\}",

year = "2017",

month = jul,

doi = "10.1016/j.semradonc.2017.03.003",

language = "English",

volume = "27",

pages = "229--239",

journal = "Seminars in radiation oncology",

issn = "1053-4296",

publisher = "W.B. Saunders Ltd",

number = "3",

}

TY - JOUR

T1 - Stereotactic Ablative Body Radiotherapy for Lung Metastases

T2 - Where is the Evidence and What are We Doing With It?

AU - Siva, Shankar

AU - Slotman, Ben J

PY - 2017/7

Y1 - 2017/7

N2 - This review provides an overview of the use of stereotactic ablative body radiotherapy (SABR) for pulmonary metastases. The local control rates after SABR are generally >90%. Whether this also translates into a significant improvement in overall survival is the subject of ongoing studies. New exciting opportunities including the integration of SABR with targeted and immune therapies as well as some competing treatment strategies are discussed.

AB - This review provides an overview of the use of stereotactic ablative body radiotherapy (SABR) for pulmonary metastases. The local control rates after SABR are generally >90%. Whether this also translates into a significant improvement in overall survival is the subject of ongoing studies. New exciting opportunities including the integration of SABR with targeted and immune therapies as well as some competing treatment strategies are discussed.

KW - Journal Article

KW - Review

U2 - 10.1016/j.semradonc.2017.03.003

DO - 10.1016/j.semradonc.2017.03.003

M3 - Review article

SN - 1053-4296

VL - 27

SP - 229

EP - 239

JO - Seminars in radiation oncology

JF - Seminars in radiation oncology

IS - 3

ER -

Stereotactic Ablative Body Radiotherapy for Lung Metastases: Where is the Evidence and What are We Doing With It?

Abstract

Keywords

Access to Document

Fingerprint

Cite this